Plain-English translation of NCT06598046 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications——to treat a type of advanced breast cancer called triple-negative that has spread to the brain. The study wants to see how well this medication combination works and whether it's safe for patients in this situation. Right now, treatment options for brain metastases from this type of breast cancer are limited, so researchers are exploring whether this combination could help.
Triple-negative breast cancer that spreads to the brain is particularly hard to treat because it doesn't respond to hormone or HER2-targeted therapies. This medication combination may be able to cross the blood-brain barrier and reach cancer cells in the brain, offering hope for patients who have limited treatment choices.
You likely qualify if…
You likely don't qualify if…
You would receive utidelone as an intravenous infusion on days 1–5 of each cycle, and capecitabine as oral tablets that you take by mouth twice daily (morning and evening) for 14 days. Each treatment cycle lasts 21 days, and you would continue this schedule as long as the treatment is working and side effects are manageable. You would have regular clinic visits for blood tests, imaging scans to measure your brain tumors, and check-ins with your doctor to monitor how you're responding to treatment.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China